» Articles » PMID: 38595825

Lysyl Oxidase-like 4 Promotes the Invasiveness of Triple-negative Breast Cancer Cells by Orchestrating the Invasive Machinery Formed by Annexin A2 and S100A11 on the Cell Surface

Abstract

Background: Our earlier research revealed that the secreted lysyl oxidase-like 4 (LOXL4) that is highly elevated in triple-negative breast cancer (TNBC) acts as a catalyst to lock annexin A2 on the cell membrane surface, which accelerates invasive outgrowth of the cancer through the binding of integrin-β1 on the cell surface. However, whether this machinery is subject to the LOXL4-mediated intrusive regulation remains uncertain.

Methods: Cell invasion was assessed using a transwell-based assay, protein-protein interactions by an immunoprecipitation-Western blotting technique and immunocytochemistry, and plasmin activity in the cell membrane by gelatin zymography.

Results: We revealed that cell surface annexin A2 acts as a receptor of plasminogen via interaction with S100A10, a key cell surface annexin A2-binding factor, and S100A11. We found that the cell surface annexin A2/S100A11 complex leads to mature active plasmin from bound plasminogen, which actively stimulates gelatin digestion, followed by increased invasion.

Conclusion: We have refined our understanding of the role of LOXL4 in TNBC cell invasion: namely, LOXL4 mediates the upregulation of annexin A2 at the cell surface, the upregulated annexin 2 binds S100A11 and S100A10, and the resulting annexin A2/S100A11 complex acts as a receptor of plasminogen, readily converting it into active-form plasmin and thereby enhancing invasion.

Citing Articles

Enhancer zeste homolog 2 (EZH2) targeting by small interfering RNA (siRNA); recent advances and prospect.

Hsu C, Mohammed A, Hjazi A, Uthirapathy S, Renuka J, Singh A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39960560 DOI: 10.1007/s00210-025-03883-9.


Pulmonary lysyl oxidase expression and its role in seeding Lewis lung carcinoma cells.

Jasmer K, Shanbhag V, Munoz Forti K, Woods L, Gudekar N, Weisman G Clin Exp Metastasis. 2024; 42(1):7.

PMID: 39714512 DOI: 10.1007/s10585-024-10325-y.


Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment.

Weijie S Discov Oncol. 2024; 15(1):783.

PMID: 39692932 PMC: 11655786. DOI: 10.1007/s12672-024-01693-8.


Enhanced design of pCMViR-TSC plasmid vector for sustainably high cargo gene expression in mammalian cells.

Sakaguchi M, Kinoshita R, Tomonobu N, Sakaguchi Y, Futami J, Yamauchi A In Vitro Cell Dev Biol Anim. 2024; 60(10):1215-1227.

PMID: 39570532 PMC: 11655592. DOI: 10.1007/s11626-024-00992-2.

References
1.
Lopez-Rodriguez J, Martinez-Carmona F, Rodriguez-Crespo I, Lizarbe M, Turnay J . Molecular dissection of the membrane aggregation mechanisms induced by monomeric annexin A2. Biochim Biophys Acta Mol Cell Res. 2018; 1865(6):863-873. DOI: 10.1016/j.bbamcr.2018.03.010. View

2.
Santibanez J, Obradovic H, Kukolj T, Krstic J . Transforming growth factor-β, matrix metalloproteinases, and urokinase-type plasminogen activator interaction in the cancer epithelial to mesenchymal transition. Dev Dyn. 2017; 247(3):382-395. DOI: 10.1002/dvdy.24554. View

3.
Chea C, Miyauchi M, Inubushi T, Okamoto K, Haing S, Takata T . Molecular Mechanisms of Inhibitory Effects of Bovine Lactoferrin on Invasion of Oral Squamous Cell Carcinoma. Pharmaceutics. 2023; 15(2). PMC: 9958951. DOI: 10.3390/pharmaceutics15020562. View

4.
Chaudhary P, Thamake S, Shetty P, Vishwanatha J . Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies. Br J Cancer. 2014; 111(12):2328-41. PMC: 4264449. DOI: 10.1038/bjc.2014.542. View

5.
Bharadwaj A, Bydoun M, Holloway R, Waisman D . Annexin A2 heterotetramer: structure and function. Int J Mol Sci. 2013; 14(3):6259-305. PMC: 3634455. DOI: 10.3390/ijms14036259. View